Arcellx (ACLX)
(Delayed Data from NSDQ)
$77.99 USD
+0.98 (1.27%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $78.03 +0.04 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ACLX 77.99 +0.98(1.27%)
Will ACLX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ACLX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACLX
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
ACLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alkermes (ALKS) Lags Q2 Earnings Estimates
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates
Other News for ACLX
Arcellx Inc’s Anito-cel Shows Promising Efficacy in Treating Challenging Multiple Myeloma, Merits Buy Rating
Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma
Arcellx initiated with an Overweight at Cantor Fitzgerald
Arcellx initiated with bullish view at Cantor Fitzgerald
Buy Rating for Arcellx Inc: Operational Efficiencies and Market Advantages Over Legend/JnJ Propel Positive Outlook